EN DE
Watch Shanghai HeartCare Med Tech for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Shanghai HeartCare Med Tech (6609) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of Shanghai HeartCare Med Tech stock HK$94.45, price HK$46.50, upside +103.1%, quality 87 out of 100. Rating: strongly undervalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · Home China · ISIN CNE100004MN5

SH Shanghai HeartCare Med Tech logo Some data Nov 8, 2026

Shanghai HeartCare Med Tech

6609 · HK
Meets all rules

The stock costs 51% less than our calculation considers fair.

Fair value HK$94.45 · Strongly undervalued
Quality 87/100
Solidly profitable · 18.1% net margin (TTM)
Generates free cash flow
Ranks above peers (11/12)
Revenue last quarter +57% vs. a year ago.
Mixed Growth (revenue 5y +94.8 %/yr in CNY)
Moderate moat 62/100 · thin data
Some data
Watch Shanghai HeartCare Med Tech for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$145.80 HK$12.32 Fair Value HK$94.45 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

60‑month range HK$12.32 – HK$145.80 · fair‑value band HK$60.32 – HK$148.74 · the HK$46.50 price screens below the HK$94.45 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.

Follow Shanghai HeartCare Med Tech in your weekly email

Every Wednesday you see whether Shanghai HeartCare Med Tech is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Shanghai HeartCare Medical Technology Corporation Limited engages in the research, development, manufacture, and sale of neuro-interventional medical devices in Mainland China.

Show moreShow less

The company offers thrombectomy stent, aspiration pump, and aspiration catheter products for the treatment of acute ischemic stroke; and intracranial drug-eluting stent, intracranial balloon dilatation catheter, intracranial low pressure balloon dilatation catheter, carotid artery balloon dilatation catheter, embolization protection system, and carotid artery stent products for the treatment of neurovascular stenosis.

It also provides embolic coil, intracranial stent, neurovascular occlusion balloon system, and flow diverter devices for the treatment of hemorrhagic stroke; left atrial appendage occluder for the prevention of ischemic stroke; and peripheral interventional devices, including fibered occlusion coil, disposable venous ablation catheter, and peripheral thrombus AP catheter.

In addition, the company provides neuro-interventional access devices, such as balloon guiding catheter, distal access catheter, microcatheter, microcatheter for coiling, microcatheter for flow diverter device, navigation catheter, vascular closure device, neuro-interventional micro, guidewire, support catheter, neuro-interventional microcatheter, radial access, catheter system, and neuro balloon delivery catheter; thrombectomy stent for the treatment of acute ischemic stroke; embolic coil for the treatment of hemorrhagic stroke.

Shanghai HeartCare Medical Technology Corporation Limited was incorporated in 2016 and is headquartered in Shanghai, the People's Republic of China.

Stock analysis

Shanghai HeartCare Med Tech (6609) currently trades at HK$46.50, while our model-based Fair Value estimate is HK$94.45, implying the stock looks roughly 51% undervalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of HK$120.41 per share, and 16 of the 24 models we run sit above the HK$46.50 price.

Bear case: the Economic Profit group reads lowest at HK$27.88, and 8 of the 24 models stay below the price. Data coverage for this calculation is medium.

Scenario range: HK$60.32 (bear) to HK$148.74 (bull), the price of HK$46.50 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 87/100 (high quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Shanghai HeartCare Med Tech reported revenue of 408M CNY in FY2025 versus 90.1M CNY in FY2021, a compound +45.9%/yr. Reported net income was 83.3M CNY in FY2025.

Key figures

Market cap HK$2.0B (≈ $258M) Micro · P/E ratio 19.0 · P/S ratio 3.88 · Net margin 20.4% · Return on equity 8.0% · Return on assets (EBIT) −6.6% (5-year average) · Operating margin 23.0% · Revenue (TTM) 514M CNY.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 62 out of 100 (low confidence).

What moves the price

The share trades about 25% below its 52-week high and 20% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at 103%, 6609 screens cheaper than that median.

Fair Value models

Bear HK$60.32 Fair Value HK$94.45 Bull HK$148.74
Price HK$46.50 · Upside +103.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF HK$73.56 HK$96.93 HK$165.71 73
Growth DCF HK$70.05 HK$103.96 HK$156.99 71
5Y EBITDA Exit HK$52.92 HK$72.22 HK$109.78 69
All 24 models by family
DCF Models
FCF DCF HK$73.56 HK$96.93 HK$165.71 73
Owner Earnings HK$66.07 HK$114.04 HK$199.69 68
5Y Revenue Exit HK$46.11 HK$58.46 HK$83.67 67
5Y EBITDA Exit HK$52.92 HK$72.22 HK$109.78 69
5Y P/E Exit HK$65.58 HK$116.77 HK$185.30 63
10Y Revenue Exit HK$55.51 HK$81.59 HK$92.85 63
10Y EBITDA Exit HK$60.32 HK$94.45 HK$148.74 62
10Y P/E Exit HK$68.44 HK$118.32 HK$197.46 57
Earnings-Based
Graham-Dodd HK$17.62 HK$122.90 HK$172.47 58
Lynch FV HK$63.49 HK$90.71 HK$117.92 57
PEG = 1.0 HK$63.49 HK$90.71 HK$117.92 53
EPV HK$27.60 HK$28.77 HK$29.73 69
Multiples
P/E Multiple HK$42.76 HK$57.02 HK$71.27 61
P/S Multiple HK$33.04 HK$44.06 HK$55.07 56
P/B Multiple HK$28.46 HK$37.94 HK$47.43 53
EV/EBIT HK$34.58 HK$40.43 HK$46.28 61
EV/EBITDA HK$40.71 HK$48.61 HK$56.51 63
EV/Revenue HK$29.55 HK$34.92 HK$40.29 50
Asset-Based
NCAV (Graham) HK$19.04 HK$28.85 HK$36.06 51
Growth DCF
Growth DCF HK$70.05 HK$103.96 HK$156.99 71
Rev-Margin DCF HK$48.50 HK$64.31 HK$97.94 67
Economic Profit
Residual Income HK$26.37 HK$26.98 HK$29.16 67
ROIC Compounder HK$27.60 HK$28.77 HK$29.73 67
Growth Earnings
Growth-Adj P/E HK$84.28 HK$120.41 HK$156.53 64

Open the full fair value analysis →

Quality Score breakdown

Overall quality 87/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 44
How much profit the company makes from its sales and capital
Quality Growth 91
Are margins and returns getting better?
Cashflow 96
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 97
Does it invest with discipline instead of growing at any price?
Low Volatility 56
How calm the share price moves, does not count
Price momentum 34
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 26
Distance to the 52-week high, does not count
New shares 86
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 85/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+46.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+30.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+94.8%
Start year 2020 (pandemic)
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,374.8% (2020) → 10.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−11.7%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about −13.2% a year for the price.

Watch 6609, get fair value alerts →

Compare Shanghai HeartCare Med Tech with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 318 stocks

Beats the industry median on 11/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 87 · Top 25%
Fair Value upside +92.8% · Top 25%
Profitability
Return on equity (12 months) 8.0% · Above median
Return on assets 6.5% · Above median
Net margin (12 months) 18.1% · Top 25%
Operating margin (12 months) 23.0% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 56.9% · Top 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/E (12 months) 19.0× · Cheaper than median
P/B 1.52× · Cheaper than median
P/S (12 months) 3.35× · Pricier than median
Price / free cash flow (fiscal year) 12.3× · Cheapest 25%
EV/EBITDA 10.3× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 6
FUTURE (revenue growth)100 · sector 36
PAST (return on equity)32 · sector 17
HEALTH (low debt)0 · sector 98
DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stryker Corporation SYK $325.87 $358.46 +10% vs 6609
Boston Scientific Corporation BSX $42.75 $47.03 +10% vs 6609
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥184.15 ¥202.57 +10% vs 6609
DexCom, Inc DXCM $79.41 $87.35 +10% vs 6609
GE HealthCare Technologies Inc GEHC $82.38 $69.92 −15% vs 6609
Edwards Lifesciences Corporation EW $102.14 $81.94 −20% vs 6609
Siemens Healthineers AG SHL €44.66 €34.51 −23% vs 6609
Abbott Laboratories, ABT $109.93 $75.28 −32% vs 6609
Medtronic plc MDT $101.80 $65.61 −36% vs 6609
Koninklijke Philips N.V PHIA €27.33 €15.23 −44% vs 6609

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Shanghai HeartCare Med Tech: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Shanghai HeartCare Med Tech Fair Value". https://www.fairvalue-calculator.com/stock/6609

Frequently asked questions

Is Shanghai HeartCare Med Tech (6609) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of HK$94.45 versus a price of HK$46.50, about +103% upside (undervalued).
What is the fair value of 6609?
Our model-based fair value for Shanghai HeartCare Med Tech is HK$94.45 (as of Nov 8, 2026), built from audited fundamentals. The current price: HK$46.50.
What is the quality score of 6609?
Shanghai HeartCare Med Tech has a Quality Score of 87/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Shanghai HeartCare Med Tech (6609)?
Our model-based price target is the fair value of HK$94.45 (as of Nov 8, 2026) from 24 valuation models. Cautious scenario HK$60.32, optimistic scenario HK$148.74. It is a calculation from audited fundamentals, not an analyst target.
What is the Shanghai HeartCare Med Tech stock forecast for 2026?
Our models put fair value at HK$94.45, about +103% upside versus a price of HK$46.50 (undervalued). Cautious scenario HK$60.32, optimistic scenario HK$148.74. The calculation is refreshed regularly with new filings.
What is the revenue of Shanghai HeartCare Med Tech (6609)?
Shanghai HeartCare Med Tech reported trailing-twelve-month revenue of about 514M CNY (latest available figure, as of Nov 8, 2026).
What growth is priced into Shanghai HeartCare Med Tech (6609)?
For today's price to be fair in a discounted-cash-flow model, Shanghai HeartCare Med Tech would have to grow free cash flow by -11.7 % per year for five years (discount rate 11.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +94.8 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of 6609 use?
Our models discount Shanghai HeartCare Med Tech at 11.9 %: a base by market capitalisation (micro), damped by beta 0.58, country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Shanghai HeartCare Med Tech that is -11.7 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.9 %) and the same formula as our fair value.
How much growth has Shanghai HeartCare Med Tech (6609) delivered so far?
Over the past 5 years revenue at Shanghai HeartCare Med Tech grew +94.8 % a year. The price currently implies free-cash-flow growth of -11.7 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Shanghai HeartCare Med Tech (6609) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Shanghai HeartCare Med Tech (-11.7 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Shanghai HeartCare Med Tech (6609)?
The free-cash-flow yield on the price is 9.38 %: that much free cash flow Shanghai HeartCare Med Tech produces per unit of market value. When it exceeds the discount rate of our models (11.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Shanghai HeartCare Med Tech (6609)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shanghai HeartCare Med Tech it is HK$94.45 per share (as of Nov 8, 2026), against a price of HK$46.50. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Shanghai HeartCare Med Tech stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 6609 trades below its calculated fair value: price HK$46.50, fair value HK$94.45, a gap of about +103% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6609?
No. The price is what the market pays today (HK$46.50); the fair value is what the company's own numbers justify (HK$94.45). For Shanghai HeartCare Med Tech the two are HK$47.95 per share apart. That gap is exactly why we show both numbers side by side.
How much is Shanghai HeartCare Med Tech worth?
The market values Shanghai HeartCare Med Tech at about HK$2.0B (market capitalisation, as of Nov 8, 2026). Per share that is HK$46.50; our models calculate a fair value of HK$94.45 per share.
What do the bullish and bearish scenarios say about 6609?
Our models span a range for Shanghai HeartCare Med Tech: cautious scenario HK$60.32, base HK$94.45, optimistic HK$148.74 per share (as of Nov 8, 2026, price HK$46.50). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 6609?
Shanghai HeartCare Med Tech trades at a price-to-earnings ratio of 19.0 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$94.45 is built from several models across several years. Other multiples: P/B 1.5, P/S 3.3, EV/EBITDA 10.3.
How solid is the balance sheet of Shanghai HeartCare Med Tech (6609)?
Balance-sheet figures for Shanghai HeartCare Med Tech (as of Nov 8, 2026): return on equity 8.0%. They feed the Quality Score of 87/100, which measures business quality independently of the share price.
How far is 6609 from its 52-week high?
Shanghai HeartCare Med Tech trades at HK$46.50, about 25% below its 52-week high of HK$62.35 and 20% above the low of HK$38.90 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of HK$94.45 is for.
Which stocks are comparable to Shanghai HeartCare Med Tech?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Shanghai HeartCare Med Tech stock attractive at the current price?
The data as of Nov 8, 2026: price HK$46.50, calculated fair value HK$94.45 (+103%), Quality Score 87/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6609 calculated?
We run Shanghai HeartCare Med Tech through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of HK$94.45 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Shanghai HeartCare Med Tech currently trades 51% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Shanghai HeartCare Med Tech (6609)?
The closing price on Nov 9, 2026 was HK$46.50. Our model-based fair value is HK$94.45, about +103% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Shanghai HeartCare Med Tech right now?
The rarer combination: high quality (87/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case (HK$60.32). The market is more pessimistic than our downside scenario. A fairly wide model range (HK$60.32 to HK$148.74) leaves room in how you read the outcome.

Key figures of Shanghai HeartCare Med Tech

How large is the market capitalisation of Shanghai HeartCare Med Tech (6609)?
The market capitalisation of Shanghai HeartCare Med Tech is HK$2.0B (≈ $258M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Shanghai HeartCare Med Tech (6609)?
The price-to-sales ratio of Shanghai HeartCare Med Tech is 3.88 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Shanghai HeartCare Med Tech (6609)?
The net margin of Shanghai HeartCare Med Tech is 20.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Shanghai HeartCare Med Tech (6609)?
The return on equity (ROE) of Shanghai HeartCare Med Tech is 8.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Shanghai HeartCare Med Tech (6609)?
On an EBIT basis the return on assets of Shanghai HeartCare Med Tech is −6.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Shanghai HeartCare Med Tech (6609)?
The operating margin of Shanghai HeartCare Med Tech is 23.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Shanghai HeartCare Med Tech (6609)?
Revenue at Shanghai HeartCare Med Tech is growing +56.9% versus a year earlier (3y avg +30.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Shanghai HeartCare Med Tech (6609)?
Earnings per share at Shanghai HeartCare Med Tech are growing +21.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Shanghai HeartCare Med Tech (6609) hold?
Shanghai HeartCare Med Tech holds more cash than debt, 547M CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Shanghai HeartCare Med Tech in the live analysis

One click puts Shanghai HeartCare Med Tech on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.